Teacher Retirement System of Texas Grows Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Teacher Retirement System of Texas boosted its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 28.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 43,877 shares of the company’s stock after purchasing an additional 9,839 shares during the quarter. Teacher Retirement System of Texas’ holdings in Allogene Therapeutics were worth $93,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. abrdn plc acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $776,000. Barclays PLC lifted its stake in Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock worth $959,000 after purchasing an additional 172,745 shares in the last quarter. Zacks Investment Management acquired a new position in shares of Allogene Therapeutics during the 3rd quarter worth approximately $1,446,000. Geode Capital Management LLC grew its position in shares of Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after purchasing an additional 407,070 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its holdings in shares of Allogene Therapeutics by 788.4% in the fourth quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company’s stock valued at $416,000 after purchasing an additional 173,457 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Insider Buying and Selling at Allogene Therapeutics

In other news, insider Timothy L. Moore sold 14,746 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the transaction, the insider now owns 250,713 shares in the company, valued at approximately $428,719.23. This represents a 5.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the sale, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. This trade represents a 5.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,866 shares of company stock valued at $194,461 in the last 90 days. Company insiders own 24.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. HC Wainwright dropped their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 19th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Friday, March 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Allogene Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $9.29.

Allogene Therapeutics Trading Up 5.1 %

Shares of NASDAQ ALLO opened at $1.44 on Thursday. The stock has a market capitalization of $312.86 million, a PE ratio of -0.92 and a beta of 1.02. Allogene Therapeutics, Inc. has a twelve month low of $1.30 and a twelve month high of $4.30. The stock has a fifty day simple moving average of $1.83 and a 200-day simple moving average of $2.22.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. On average, equities analysts predict that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).